This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Antigen-specific antitumor responses induced by OX40 agonist are enhanced by IDO
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
and suppressor arms of the immune system synergistically promotes tumor eradication.
This translatable strategy may enhance the overall efficacy of cancer treatment.
Acknowledgments
The authors thank Rhea-Beth Markowitz, Charles C. Berrong and Seema Gupta for
reviewing the manuscript.
References
1. Naito, Y., et al., CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res, 1998. 58(16): p. 3491-4.
2. Carretero, R., et al., Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8 T cells. Nat Immunol, 2015.
3. Romano, E., et al., Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A, 2015.
4. Burns, W.R., et al., A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res, 2010. 70(8): p. 3027-33.
5. Almasbak, H., et al., Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. Gene Ther, 2015. 22(5): p. 391-403.
6. Hombach, A.A. and H. Abken, Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer. Immunotherapy, 2013. 5(7): p. 677-81.
7. Hombach, A.A., et al., OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology, 2012. 1(4): p. 458-466.
8. Chacon, J.A., et al., Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One, 2013. 8(4): p. e60031.
9. Mallett, S. and A.N. Barclay, A new superfamily of cell surface proteins related to the nerve growth factor receptor. Immunol Today, 1991. 12(7): p. 220-3.
10. www.clinicaltrials.gov. 2015; Available from: www.clinicaltrials.gov. 11. Sleckman, B.P., et al., Expression and function of CD4 in a murine T-cell
hybridoma. Nature, 1987. 328(6128): p. 351-3. 12. Mallett, S., S. Fossum, and A.N. Barclay, Characterization of the MRC OX40
antigen of activated CD4 positive T lymphocytes--a molecule related to nerve growth factor receptor. EMBO J, 1990. 9(4): p. 1063-8.
13. Croft, M., Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol, 2010. 28: p. 57-78.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
14. Gramaglia, I., et al., Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol, 1998. 161(12): p. 6510-7.
15. Gramaglia, I., et al., The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol, 2000. 165(6): p. 3043-50.
16. Rogers, P.R., et al., OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity, 2001. 15(3): p. 445-55.
17. Sugamura, K., N. Ishii, and A.D. Weinberg, Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol, 2004. 4(6): p. 420-31.
18. Curti, B.D., et al., OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res, 2013. 73(24): p. 7189-98.
19. Weinberg, A.D., et al., Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol, 2000. 164(4): p. 2160-9.
20. Gough, M.J., et al., OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res, 2008. 68(13): p. 5206-15.
21. Piconese, S., B. Valzasina, and M.P. Colombo, OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med, 2008. 205(4): p. 825-39.
22. Humphreys, I.R., et al., OX40 costimulation promotes persistence of cytomegalovirus-specific CD8 T Cells: A CD4-dependent mechanism. J Immunol, 2007. 179(4): p. 2195-202.
23. Biagi, E., et al., Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes. Blood, 2005. 105(6): p. 2436-42.
24. Draghiciu, O., H.W. Nijman, and T. Daemen, From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors. Clin Dev Immunol, 2011. 2011: p. 439053.
25. Mellman, I., G. Coukos, and G. Dranoff, Cancer immunotherapy comes of age. Nature, 2011. 480(7378): p. 480-9.
26. Topfer, K., et al., Tumor evasion from T cell surveillance. J Biomed Biotechnol, 2011. 2011: p. 918471.
27. Uyttenhove, C., et al., Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med, 2003. 9(10): p. 1269-74.
28. Munn, D.H. and A.L. Mellor, IDO and tolerance to tumors. Trends Mol Med, 2004. 10(1): p. 15-8.
29. Harlin, H., et al., Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother, 2006. 55(10): p. 1185-97.
30. Polak, M.E., et al., Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer, 2007. 96(12): p. 1879-87.
31. Weinlich, G., et al., Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology, 2007. 214(1): p. 8-14.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
32. Thaker, A.I., et al., IDO1 metabolites activate beta-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice. Gastroenterology, 2013. 145(2): p. 416-25 e1-4.
33. Munn, D.H., et al., Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest, 2004. 114(2): p. 280-90.
34. Fallarino, F., et al., T cell apoptosis by tryptophan catabolism. Cell Death Differ, 2002. 9(10): p. 1069-77.
35. Frumento, G., et al., Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med, 2002. 196(4): p. 459-68.
36. Terness, P., et al., Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med, 2002. 196(4): p. 447-57.
37. Munn, D.H., et al., Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science, 2002. 297(5588): p. 1867-70.
38. Munn, D.H. and A.L. Mellor, Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest, 2007. 117(5): p. 1147-54.
39. Friberg, M., et al., Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer, 2002. 101(2): p. 151-5.
40. Muller, A.J., et al., Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med, 2005. 11(3): p. 312-9.
41. Mkrtichyan, M., et al., Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol, 2011. 41(10): p. 2977-86.
42. Sharma, P., et al., Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer, 2011. 11(11): p. 805-12.
43. Mkrtichyan, M., et al., B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets. J Immunol, 2012. 189(5): p. 2338-47.
44. Mkrtichyan, M., et al., Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy. J Immunother Cancer, 2013. 1: p. 15.
45. Curran, M.A., et al., PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A, 2010. 107(9): p. 4275-80.
46. Godin-Ethier, J., et al., Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res, 2011. 17(22): p. 6985-91.
47. Alexander, J., et al., Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J Immunol, 2000. 164(3): p. 1625-33.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
48. Hoshi, M., et al., The absence of IDO upregulates type I IFN production, resulting in suppression of viral replication in the retrovirus-infected mouse. J Immunol, 2010. 185(6): p. 3305-12.
49. Spranger, S., et al., Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med, 2013. 5(200): p. 200ra116.
50. Munn, D.H., et al., Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med, 1999. 189(9): p. 1363-72.
51. Bulliard, Y., et al., OX40 engagement depletes intratumoral Tregs via activating FcgammaRs, leading to antitumor efficacy. Immunol Cell Biol, 2014. 92(6): p. 475-80.
52. Shen, Z., et al., Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. J Cancer Res Clin Oncol, 2010. 136(10): p. 1585-95.
Figure legends
Figure 1. Combination of vaccine, anti-OX40 Ab and indoximod provides potent
antitumor therapeutic efficacy. A. C57BL/6 mice (n = 5/group) were injected s.c. in the
right flank with 7x104 TC-1 cells. Mice from appropriate groups were injected weekly with
vaccine (s.c.) or PBS as a control into the right flank. Anti-OX40 was injected i.p. twice a
week starting on Day 10 after tumor implantation throughout the experiment. Indoximod
was provided in drinking water starting Day 10 throughout the experiment. Tumor sizes
were measured every 3-4 days. B. Plots represent tumor volumes of individual mice for
each treatment. Ratio on the plots shows number of mice with completely regressed
tumors over total number of mice in the group. Average tumor volumes ± SD on days 26
(C) and 40 (D). E. Kaplan–Meier plot of the overall survival. Similar results were
obtained from two independent experiments. *P < 0.05, ** P < 0.01. Experiment was
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223
Published OnlineFirst January 5, 2018.Cancer Immunol Res Zuzana Berrong, Mikayel Mkrtichyan, Shamim Ahmad, et al. are enhanced by IDO inhibitor indoximod.Antigen-specific antitumor responses induced by OX40 agonist
Updated version
10.1158/2326-6066.CIR-17-0223doi:
Access the most recent version of this article at:
Manuscript
Authoredited. Author manuscripts have been peer reviewed and accepted for publication but have not yet been
E-mail alerts related to this article or journal.Sign up to receive free email-alerts
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://cancerimmunolres.aacrjournals.org/content/early/2018/01/05/2326-6066.CIR-17-0223To request permission to re-use all or part of this article, use this link
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 5, 2018; DOI: 10.1158/2326-6066.CIR-17-0223